Leslie L. Citrome, M.D., M.P.H., is a distinguished life fellow of the American Psychiatric Association and a fellow of the American Society of Clinical Psychopharmacology, where he currently serves as immediate past president. He is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. In 2019, Dr. Citrome received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science)”. In 2018, 2021, and 2023, Dr. Citrome was recognized as the Voluntary Faculty Teacher of the Year in the Department of Psychiatry and Behavioral Sciences at New York Medical College/Westchester Medical Center.

Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of the number needed to treat and the number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australia. Dr. Citrome’s main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is an author and co-author of more than 600 research reports, reviews, and chapters in the scientific literature. He is a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; and also serves as an editorial board member for 11 other journals.

Education

• DEC, Pure and Applied Science, Dawson College
• M.D., McGill University Faculty of Medicine
• M.P.H., Columbia University School of Public Health
• Residency, Psychiatry, New York University

Areas of Expertise

• Mental Health Disorders

Publications

• Citrome L, Neugebauer NM, Meli AA, et. al. "Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed." Neuropsychiatric disease and treatment, 21(), (2025) 761-773. doi: 10.2147/NDT.S503494
• de Leon J, Baldessarini RJ, Balon R, et. al. "Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes." Journal of clinical psychopharmacology, (), (2025) . doi: 10.1097/JCP.0000000000001990
• de Leon J, Baldessarini RJ, Balon R, et. al. "Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes." Journal of clinical psychopharmacology, (), (2025) . doi: 10.1097/JCP.0000000000001987
• Faden J, Citrome L. "A new paliperidone palmitate formulation: how is it different and where does it fit in our array of choices for long-acting formulations of risperidone and paliperidone?" Current medical research and opinion, (), (2025) 1-4. doi: 10.1080/03007995.2025.2482654
• Madden S, Citrome L, Correll CU, et. al. "A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males." The Journal of clinical psychiatry, 86(2), (2025) . pii: 24m15665. doi: 10.4088/JCP.24m15665
• Citrome L, Correll CU, Cutler AJ, et. al. "Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia." Neuropsychiatric disease and treatment, 21(), (2025) 575-596. doi: 10.2147/NDT.S499367
• Kaul I, Sawchak S, Claxton A, et. al. "Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials." Schizophrenia (Heidelberg, Germany), 11(1), (2025) 44. doi: 10.1038/s41537-025-00595-0

View All Publications

Memberships and Affiliations

• Distinguished Life Fellow of the American Psychiatric Association
• Fellow of the American Society of Clinical Psychopharmacology
• Fellow (Emeritus), Collegium Internationale Neuro-Psychopharmacologicum (CINP)